Odyssey Math Tuition launches a Secondary 2 online math tuition elearning course in Singapore, featuring a proprietary ...
Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...
TipRanks on MSN
Vertex options imply 6.1% move in share price post-earnings
Pre-earnings options volume in Vertex is 2.7x normal with calls leading puts 10:9. Implied volatility suggests the market is anticipating a move ...
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...
Tylah Tully looks at Vertex Minerals and its growing high-grade gold production in the latest episode of Stockhead's Who’s ...
Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...
The company posted revenue of $192.1 million in the period, which beat Street forecasts. Five analysts surveyed by Zacks expected $191.5 million. For the current quarter ending in December, Vertex ...
Get insights from Vertex Pharmaceuticals' Q3 2025 earnings call—revenue growth, pipeline milestones, and outlook for ALYFTREK, CASGEVY, and JOURNAVX.
Investor's Business Daily on MSN
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book
Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback